Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: Evidence for role in era of standard adjuvant temozolomide

Core Evidence

Volumn 7, Issue , 2012, Pages 115-130

  Kleinberg, Lawrence ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Carmustine; Malignant glioma; Polifeprosan 20

Indexed keywords

CARMUSTINE; PLACEBO; POLIFEPROSAN; TEMOZOLOMIDE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; CRANIOTOMY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; IMPLANT; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; SLOW RELEASE FORMULATION; WAFER;

EID: 84873197301     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S23244     Document Type: Review

References (82)

1. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88. (Pubitemid 36422560)
2. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E, Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148(3):269-275. (Pubitemid 43341024)
3. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet. 1995;345(8956):1008-1012.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
6. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333-343. (Pubitemid 9013313)
7. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303(23):1323-1329. (Pubitemid 11194457)
8. Burger PC. Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin Oncol. 1986;13(1):16-26. (Pubitemid 16116037)
9. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000;26(6):397-409. (Pubitemid 32094859)
10. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35-58.
11. Buonerba C, Di Lorenzo G, Marinelli A, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol. 2011;80(1):54-68.
12. Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol. 2011;17(3):286-295.
13. Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol. 2011; 38 Suppl 4:S2-S10.
14. Buonerba C, Di Lorenzo G, Marinelli A, et al. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol. 2011;80(1):54-68.
15. National Institute for Health and Clinical Excellence. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma. Available from: www.nice.org.uk/TA121. Accessed March 18, 2012.
16. Salvati M, D'elia A, Frati A, Brogna C, Santoro A, Delfini R. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. J Neurosurg Sci. 2011;55(1):1-6.
17. Salmaggi A, Duri S, Silvani A, et al. Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. Neurol Sci. 2011;32 Suppl 2:S241-S245.
18. Perry J, Chambers A, Spithoff K, Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol. 2007;14(5):189-194.
19. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008;88(3):353-357.
20. Noel G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys. 2012;82(2):749-755.
21. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol. 2010;17(7):1740-1746.
22. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
23. McGirt MJ, Brem H. Carmustine wafers (gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol. 2010;17(7):1729-1731.
24. Affronti ML, Heery CR, Herndon JE II, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115(15):3501-3511.
25. Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010;33(4):441-449.
26. Dixit S, Hingorani M, Achawal S, Scott I. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys. 2011;81(5):1593.
27. Domb AJ, Rock M, Perkin C, Yipchuck G, Broxup B, Villemure JG. Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. Biomaterials. 1995;16(14):1069-1072.
28. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403-419. (Pubitemid 34753678)
29. Gopferich A. Erosion of composite polymer matrices. Biomaterials. 1997;18(5):397-403. (Pubitemid 27095586)
30. Noel G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys. 2012;82(2):749-755.
31. La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin. 2009;25(1):149-160.
32. Domb AJ, Israel ZH, Elmalak O, Teomim D, Bentolila A. Preparation and characterization of carmustine-loaded polyanhydride wafers for treating brain tumors. Pharm Res. 1999;16(5):762-765. (Pubitemid 29227109)
33. Domb AJ, Rock M, Schwartz J, et al. Metabolic disposition and elimination studies of a radiolabelled biodegradable polymeric implant in the rat brain. Biomaterials. 1994;15(9):681-688. (Pubitemid 24230608)
34. Domb A. Gliadel - a preparation for the supplementary treatment of brain cancer. Harefuah. 1999;137(3-4):127-131.
35. Brown LR, Wei CL, Langer R. In vivo and in vitro release of macromolecules from polymeric drug delivery systems. J Pharm Sci. 1983;72(10):1181-1185. (Pubitemid 13013638)
36. Domb A, Maniar M, Bogdansky S, Chasin M. Drug delivery to the brain using polymers. Crit Rev Ther Drug Carrier Syst. 1991;8(1):1-17.
37. Laurencin C, Domb A, Morris C, et al. Poly(anhydride) administration in high doses in vivo: studies of biocompatibility and toxicology. J Biomed Mater Res. 1990;24(11):1463-1481. (Pubitemid 20359834)
38. Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008;8(3):343-359. (Pubitemid 351836283)
39. Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res. 1996;13(5):683-691. (Pubitemid 26160095)
40. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg. 1992;76(4):640-647.
41. Hunter KJ, Deen DF, Pellarin M, Marton LJ. Effect of alpha- difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro. Cancer Res. 1990;50(9):2769-2772. (Pubitemid 20150220)
42. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res. 1996;13(5):671-682. (Pubitemid 26156217)
43. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403-419. (Pubitemid 34753678)
44. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998;58(4):672-684. (Pubitemid 28099477)
45. Buahin KG, Brem H. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. J Neurooncol. 1995;26(2):103-110. (Pubitemid 26003221)
46. Brem H, Mahaley MS Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991;74(3):441-446.
47. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet. 1995;345(8956):1008-1012.
48. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011;3:CD007294.
49. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev. 2008;3:CD007294.
50. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12(8):871-881.
51. Olivi A, Grossman SA, Tatter S, et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS Consortium Trial. J Clin Oncol. 2003;21(9):1845-1849. (Pubitemid 46638598)
52. Brem H, Tamargo RJ, Olivi A, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg. 1994;80(2):283-290. (Pubitemid 24036500)
53. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol. 1995;26(2):111-123. (Pubitemid 26003222)
54. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997;41(1):44-48.
55. Kleinberg LR, Weingart J, Burger P, et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest. 2004;22(1):1-9. (Pubitemid 38523954)
56. Gunjur A, Lau E, Taouk Y, Ryan G. Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. J Med Imaging Radiat Oncol. 2011;55(6):603-610.
57. Chamberlain MC. Pseudoprogression in glioblastoma. J Clin Oncol. 2008;26(26):4359.
58. Sanghera P, Rampling R, Haylock B, et al. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (R Coll Radiol). 2012;24(3):216-227.
59. Chaichana KL, Zaidi H, Pendleton C, et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res. 2011;33(7):759-764.
60. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887-2893.
61. Giese A, Bock HC, Kantelhardt SR, Rohde V. Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg. 2010;71(4):199-206.
62. Colen RR, Zinn PO, Hazany S, et al. Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: a pilot study. World J Radiol. 2011;3(11):266-272.
63. Hammoud DA, Belden CJ, Ho AC, et al. The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. AJR Am J Roentgenol. 2003;180(5):1469-1475. (Pubitemid 36504646)
64. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol. 2001;3(4):246-250. (Pubitemid 33674145)
65. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
66. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii-iv, ix-221.
67. Arifin DY, Lee KY, Wang CH, Smith KA. Role of convective flow in carmustine delivery to a brain tumor. Pharm Res. 2009;26(10):2289-2302.
68. Brem S, Tyler B, Li K, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 2007;60(5):643-650. (Pubitemid 47247276)
69. Walter KA, Cahan MA, Gur A, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994;54(8):2207-2212. (Pubitemid 24138696)
70. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C, Brem H. Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J Neurooncol. 1997;32(3):181-192. (Pubitemid 27077968)
71. Yuan X, Dillehay LE, Williams JR, Williams JA. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma. Cancer Biother Radiopharm. 1999;14(3):187-202. (Pubitemid 29288366)
72. Sampath P, Rhines LD, DiMeco F, Tyler BM, Park MC, Brem H. Interstitial docetaxel (Taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.J Neurooncol. 2006;80(1):9-17. (Pubitemid 44473256)
73. Storm PB, Moriarity JL, Tyler B, Burger PC, Brem H, Weingart J. Polymer delivery of camptothecin against 9 L gliosarcoma: release, distribution, and efficacy. J Neurooncol. 2002;56(3):209-217. (Pubitemid 34476989)
74. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9 L gliosarcoma model. Int J Cancer. 1995;62(5):605-609.
75. Yuan X, Tabassi K, Williams JA. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma. Radiat Oncol Investig. 1999;7(4):218-230. (Pubitemid 29427198)
76. Weingart J, Grossman SA, Carson KA, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS Consortium Trial. J Clin Oncol. 2007;25(4):399-404. (Pubitemid 350002988)
77. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A Phase I trial of surgery, gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol. 2005;72(3):241-244. (Pubitemid 40867407)
78. Cohen L, Cokgor I, Kerby T, Rich J, Stewart E. Phase I trials of gliadel plus CPT-11 or temodal (temozolomide). Proceedings of the American Society of Clinical Oncology. 1999:573.
79. Smith KA, Ashby LS, Gonzalez LF, et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative gamma knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg. 2008;Suppl 109:106-117.
80. National Cancer Institute. NCT01186406: Gliadel, XRT, temodar, avastin followed by avastin, temodar for newly diagnosed glioblastoma multiforme (GBM). Available from: http://www.cancer.gov/clinicaltrials. Accessed March 18, 2012.
81. NCT00660621: A Phase II study of Gliadel, concomitant temozolomide and radiation, followed by dose dense therapy with temozolomide plus bevacizumab for newly diagnosed malignant high grade glioma. Available from: www.cancer.gov/clinicaltrials. Accessed March 18, 2012.
82. Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res. 2007;13(12):3637- 3641. (Pubitemid 46955127)